Inclusion Criteria:  Resident in Digaale camp Voluntary written/thumb-printed informed consent has been provided by a parent or caretaker; Subject's parent must be able to comprehend and comply with study requirements and procedures; Subject's parents must have a readily identifiable place of residence in the study area, be available for the duration of study participation, and have a means of telephone contact  Exclusion Criteria:  Known hypersensitivity to any component of the vaccine, including diphtheria toxoid; History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines. This includes such reactions in older siblings and also includes all components of the Expanded Programme of Immunization vaccines; History of anaphylactic shock; Any abnormal (Grade ≥ 1) vital sign. Note: An abnormal vital sign, including fever (axillary temperature of ≥ 37.5°C), may be repeated to determine whether a subject is eligible for vaccination. A minimum of 48 hours following a documented fever must pass before the subject can be reassessed for eligibility. Any moderate or severe (Grade ≥ 2) acute illness. Note: Infants with a Grade 1 acute illness may be enrolled at the discretion of the PI. Note: Subjects with moderate or severe acute illness may return for clinical re-assessment; if the illness has sufficiently resolved, they may still qualify for vaccination. Chronic administration (defined as more than 14 consecutive days) of immunosuppressant or other immune modifying drugs prior to the administration of the study vaccine, including the use of glucocorticoids. The use of topical and inhaled glucocorticoids is not an exclusion criterion.